Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo

Journal article

KILTIE A. et al, (2020), International Journal of Radiation: Oncology - Biology - Physics

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo

Journal article

KILTIE A. et al, (2020), International Journal of Radiation: Oncology - Biology - Physics

MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer

Journal article

Walker AK. et al, (2019), International Journal of Radiation Oncology*Biology*Physics

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.

Journal article

Hermans TJN. et al, (2018), Urol Oncol, 36, 413 - 422

Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future

Journal article

Hermans TJN. et al, (2018), UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 36, 413 - 422

Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer.

Journal article

Harshman LC. et al, (2018), Clin Genitourin Cancer, 16, 213 - 218

Load More